

IN THE CLAIMS

1 (Currently Amended). A nona or decapeptide which appears in the sequence of ~~derived from a protein selected from the group consisting of Uroplakin (UP), Prostate specific antigen (PSA), Prostate specific membrane antigen (PSMA), Prostate acid phosphatase (PAP), Lactadherin (BA-46), Mucin (MUC1) and Teratocarcinoma-derived growth factor (CEIPTO-1), the~~ which peptide is selected so as to promote effective binding to a MHC class 1 type molecule so as to elicit a CTL response comprising 8 to 10 amino acid residues, of which a second residue from an amino terminal of the peptide and an end residue at a carboxy terminal of the peptide are hydrophobic or hydrophilic natural or non-natural amino acid residues, with the proviso that for PSA, SEQ ID NOs 20 and 24 are excluded, for PSMA, SEQ ID NOs 25, 26, 27, 29 and 30 are excluded and for PAP, SEQ ID NOs 31, 32, 33 and 34 are excluded.

Claims 2-15 (Cancelled)

2. 16 (Currently Amended). The peptide of claim 1 ~~15~~, wherein ~~the peptide has a sequence selected from the group consisting of SEQ ID NOs: 35-41~~ 35, 36, 37, 38, 39, 40, 41 or 41.

Claims 17-18 (Cancelled)

19 (Previously Amended). The peptide of claim 1, wherein said peptide is derived from a mammal.

20 (Currently Amended). The peptide of claim 19,

wherein the mammal is a humanoid ~~and~~ or a rodent.

21(Previously Amended). The peptide of claim 1, wherein said peptide includes at least one non-natural modification.

Claim 22 (Cancelled)

23(Currently Amended). The peptide of claim 21, wherein said at least one modification is selected from the group consisting of peptoid modification, ~~semipeptoid modification,~~ cyclic peptide modification, N terminus modification, C terminus modification, peptide bond modification, backbone modification and residue modification.

24(Previously Amended). A pharmaceutical composition comprising, as an active ingredient, at least one peptide as set forth in claim 1 and a pharmaceutically acceptable carrier.

Claim 25 (Cancelled)

26(Previously Amended). The pharmaceutical composition of claim 24, wherein the composition is effective to inhibit cancer or cancer metastases.

27(Original). The pharmaceutical composition of claim 26, wherein said cancer is selected from the group consisting of breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach and head and neck cancer.

28(Original). The pharmaceutical composition of claim 26, wherein said cancer is a carcinoma.

29(Original). The pharmaceutical composition of claim 24, wherein the composition is a vaccine.

30(Previously Amended). A vaccine composition comprising, as an active ingredient, at least one peptide as set forth in claim 1 and a suitable carrier.

(13) 31(Currently Amended). The vaccine composition of claim 30, wherein said carrier is selected from the group consisting of a proteinaceous carrier to which said at least one ~~tumor associated antigen~~ peptide is linked, an adjuvant, a protein or a recombinant protein and an antigen presenting cell.

(14) 32(Currently Amended). The vaccine composition of claim 30, wherein the composition is ~~contains an amount of said~~ ~~peptide~~ effective to inhibit cancer or cancer metastases.

33(Original). The vaccine composition of claim 32, wherein said cancer is selected from the group consisting of breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach and head and neck cancer.

34(Original). The vaccine composition of claim 32, wherein said cancer is a carcinoma.

Claims 35-43 (Cancelled)

44(Original). The peptide of claim 1, wherein the second residue and the end residue are neutral, hydrophobic and aliphatic.

45 (Currently Amended). The pharmaceutical composition of claim 24 also comprising a helper peptide having a helper T cell epitope.

Claims 46-51 (Cancelled)

52 (Currently Amended). A peptide which appears in the sequence of a tumor-associated antigen derived from a protein selected from the group consisting of Uroplakin (UP), Prostate specific antigen (PSA), Prostate specific membrane antigen (PSMA), Prostate acid phosphatase (PAP), Lactadherin (BA-46) and Mucin (MUC1) and Teratocarcinoma-derived growth factor (CRIPTO-1), the peptide consisting of comprising 8-9 or 10 amino acid residues as-selected so as to promote effective binding to a MHC class 1 type molecule such that so as to elicit a CTL response.

53 (New). The pharmaceutical composition of claim 26, wherein said cancer is breast cancer.

54 (New). The vaccine composition of claim 32, wherein said cancer is breast cancer.